Fruit flies help explain why diet success varies

By Lorraine Heller, 29-Jul-2010


A study on fruit flies has indicated that genetic interaction with diet has a greater impact on body weight than diet alone, which the researchers say can help explain different reactions to similar diets.

Published in the July issue of Genetics, the study adds weight to the theory of personalised nutrition, which suggests that the benefit of nutritional compounds varies for different people.

“This study strongly suggests that some individuals can achieve benefits from altering their dietary habits, while the same changes for others will have virtually no effect,” write the researchers.

Different genetic lines

Led by Laura Reed, Ph.D, from the Department of Genetics at North Carolina State University, the researchers studied 146 different genetic lines of fruit flies to contrast quantitative genetic mechanisms with respect to weight gain.

The flies were fed four different diets: nutritionally balanced, low calorie, high sugar, and high fat. Researchers then measured a variety of metabolic traits, including body weight, in each group.

Findings indicated that diet alone made a small contribution to the total variation in metabolic traits, while genotype and genotype interactions with diet made “very large” contributions.

Flies in some of the genetic lines were “highly sensitive” to their diets, as reflected by changes in body weight, while flies of other lines showed no change in weight across diets.

For several metabolic traits, genotype-by-diet interactions accounted for far more variance (between 12 and 17 per cent) than diet alone (1–2 per cent), and in some cases have as large an effect as genetics alone (11–23 per cent), reported the researchers.

One size doesn’t fit


“There is no one-size-fits all solution to the diseases of obesity and type-2 diabetes,” said Reed.

“Each person has a unique set of genetic and environmental factors contributing to his or her metabolic health, and as a society, we should stop looking for a panacea and start accepting that this is a complex problem that may have a different solution for each individual.”



Exclusive interview with Board ChairmanYu

from Asia Pacific Food Industry

1. What makes the company stand out from other competitors?

The company’s growth is fuelled largely by three aspects. Firstly, the rapid growth of the Chinese economy and a good domestic environment for enterprise development helps to drive the company forward.

Secondly, the company directs a great deal of attention towards technological progress. As a result, a large number of highly competitive products are developed, such as sugar-tolerant instant dry yeast, super alcohol active dry yeast, selenium yeast 2000, and yeast glucan.

Finally, our marketing activities are centred on market orientation and profit seeking for customers, which are also core values of the employees.

2. Could you share with us more on your R&D activities?

Research and design activities for products and technology application are dedicated to improving the quality of life by providing natural, nutritious and healthy food ingredients.

The business prospects result from many our research projects. An example is the aluminium-free leavening agent project, which was used to solve aluminium problems in Youtiao (Chinese fried dough stick).

Additionally, the yeast extract meets the market demand in Clean Label EU and the salt-reduction trend.

3. What are the trends that we can expect to see from the baking industry within the next 5 years?

In future, we can expect more in the development of products based on health. Through co-operation with the other players in the industry, together we can promote product diversity, spread the concept of healthy living, and promote progress in technology.

In order to keep up with this trend, we will always adhere to the idea ‘natural, nutrition & health’ in product development.

4. What is the company’s expansion plans?

The company will base itself upon the home market first, since China is one of the globe’s largest economies. The domestic market was, and will still be our marketing focus in future.

Additionally, we will further develop our presence in the international market. Currently, our products are exported to more than 120 countries and regions via sales agents established in all continents. We still have a long way to go in global marketing, a huge yeast market overseas for us to explore.

Our marketing plans shall correspond with the globalisation trend gradually. Not only in terms of sales network, but more importantly, the company shall meet the conditions for total internationalisation development, including R&D, management, production and marketing.

At present, construction of the yeast plant in Egypt is most important for Angel Yeast. The Egypt project shall be a key milestone for us in achieving the goal as an international, professional yeast company.

5. What are the current challenges facing the company?

The challenges are mainly in three areas. Firstly, the growing cost for raw materials and energy. It is well known that yeast production costs increased sharply due to the global yeast capacity expansion and reduction of energy resources.

Secondly, the company is facing pressure from the increased valuation of the RMB currency. Lastly, we are faced with challenges in coping with the first overseas yeast plant construction in Egypt, and our global operations, as these are new areas for us.

6. What are the company’s plans to cope with this?

We have realised and understood the situation, and so preparations have been made to meet those challenges.

We will intensify our efforts in promoting new products. The brand influence will be further established in various ways, with multiple-business development and improved marketing.

Up-to-date technology, process & new materials shall also be put into operation, further reducing production costs through technological progress.

The company’s management and capital efficiency shall also be improved by incorporating tools such as SAP and CRM system into the daily operations.

7. What is the company’s forecast for 2010?

Angel Yeast business growth shall last continuously through the efforts both from market development and other aspects.

R&D of Angel yeast

Global Network

Brief Introduction to Angel Chengdu New Technology Center

by Angel

Angel Yeast Chengdu New Technology Center is located in Chengdu Headquarters-base, with the building area of 2900m2.Will be completely established in the latter half of the year 2009.

Angel Yeast Chengdu New Technology Center is an important branch established on the basis of “internationalized and specialized” strategic development, and serves as Southwest China sales and services center. Meanwhile, it will be a window of Angel to have a foothold in the leading position of yeast industry, closely follow in the forefront of industrial information, actively strengthen the user applied technology service and focus on displaying Angel brand and image. Its training Center can accommodate about 40 people for learning and operating at the same time, as an ideal place for applied technology training, it owns multi-media classrooms, complete training facilities and advanced operating equipments.





Angel Today Global Network

by Angel

Angel has built 6 factories and 4 tech. centers in china. Our marketing service agencies spread over every provincia capital in China, and

products are sold to over 120 countries and regions worldwide.



Venus to supply docetaxel to Thailand

By Nick Taylor


Venus Remedies is supplying docetaxel to Thailand after a compulsory license was issued to make the drug more affordable.

Sanofi-Aventis holds the patent for docetaxel, which it markets as Taxotere, but the Government Pharmaceutical Organization (GPO) of Thailand has issued a compulsory license to cut treatment cost. The GPO intends to distribute docetaxel to citizens unable to afford the cost of treatment.

India-based Venus has been contracted to manufacture and supply docetaxel to the GPO. Venus said it won the contract in an open bidding system despite competition from a Germany-based multi-national pharmaceutical company.

The GPO has conducted an audit of Venus’ manufacturing facility and confirmed it meets international standards. Having completed this step Venus plans to begin shipping docetaxel in November 2010.

The contract is valid for one year and is expected to generate a business of more than Rs 100m ($2.2m) to the company. We have tie-up with a local pharmaceutical group for marketing and distribution of the product to the entire Thai market”, said Pawan Chaudhary, CMD at Venus.

Winning the contract builds on Venus’ presence in Thailand. Venus has 10 product registrations in Thailand for oncology and anti-infective treatments.

Patents granted, patents invalidated


Earlier this month Venus was granted a patent in the European Union for its anti-infective Sulbactomax. Having secured the patent, which is valid until 2025, Venus plans to enter the EU market in 2013 through the common technical document (CTD) route.

On the other side of the Atlantic a US court ruled two Sanofi patents covering the formulation of Taxotere are invalid. A patent covering the active pharmaceutical ingredient (API) is valid until November but after this a generic version could become available.

Previous Older Entries Next Newer Entries